The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Trump administration officials are making statements that some advocacy and medical groups say depict patients and the ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , ...

Discover how weight loss medications and smart nutrition can silence cravings in Food Noise by Dr. Jack Mosley.